Skip to main content
Publications
Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho C, Reynolds M, Sherif B, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030
Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021 Jul 14;154:138-46.
Bommireddy R, Pack CD, Bozeman EN, Patel JM, Vartebedian VF, Munoz LE, Shafizadeh Y, Menon AP, Lakshmanan R, Reddy SJC, Selvaraj P. Membrane-based immunotherapy with immune checkpoint blockade antibodies confers protection against metastatic breast cancer. Poster presented at the Immunology 2017 Meeting; May 12, 2017. Washington, DC. [abstract] J Immunol. 2017 May 1; 198(1_Supplement):120.8. doi: 10.4049/jimmunol.198.Supp.120.8
Munoz LE, Bommireddy R, Margaroli C, Shafizadeh Y, Bozeman EN, Menon AP, Kumar J, Lakshmanan R, Selvaraj P. HER-2+ breast cancer cells expressing GPI-anchored cytokines induce long lasting antitumor memory response. Poster presented at the Immunology 2017 Meeting; May 12, 2017. Washington, DC. [abstract] J Immunol. 2017 May 1; 198(1_Supplement):79.28. Previously presented at the International Congress of Immunology (ICI) 2016. doi: 10.4049/jimmunol.198.Supp.79.28
Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, Martin-Richard M, Cid J, Lozano M, Castells A, Garcia-Albeniz X, Maurel J, Vilella R. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016 Sep;64:167-74. doi: 10.1016/j.ejca.2016.06.008
Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P, Castells A, Lozano JJ, Rosell R, Maurel J. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019